| Literature DB >> 18315853 |
Chen Wang1, Jianhua Xuan, Li Chen, Po Zhao, Yue Wang, Robert Clarke, Eric Hoffman.
Abstract
BACKGROUND: Network Component Analysis (NCA) has shown its effectiveness in discovering regulators and inferring transcription factor activities (TFAs) when both microarray data and ChIP-on-chip data are available. However, a NCA scheme is not applicable to many biological studies due to limited topology information available, such as lack of ChIP-on-chip data. We propose a new approach, motif-directed NCA (mNCA), to integrate motif information and gene expression data to infer regulatory networks.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18315853 PMCID: PMC2259422 DOI: 10.1186/1471-2105-9-S1-S21
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Figure 1An illustrative example for the NCA approach as in muscle regeneration studies. The network topology is formed by the connection matrices of the transcription factors (TFs) such as YY1 and MyoD to their target genes as shown in (a). The main objective of the NCA approach is to estimate the transcription factors' activities (TFAs) and their target genes via the estimated connection matrices as shown in (b).
Mouse muscle related transcription factors obtained from the TRANSFAC 11.1 Professional database.
| Index | Regulatory Site | TRANSFAC Matrix ID | Brief Description |
| 1 | YY1 | M01035, M00059, M00069, M00793 | Ying Yang 1; common factor 1; delta-factor; F-ACT1; myc-CF1; NF-E1 |
| 2 | Tal-1 alpha:E47 | M00066 | Tal-1beta:E47 heterodimer. Random 35-mers bound by in vitro co-translated Tal-1alpha and E47 after 6 CASTing cycles |
| 3 | NF-Y | M00775, M00185, M00287, M00209 | Nuclear Factor Y; CCAAT-binding factor; CP1 |
| 4 | Alpha-CP1 | M00687 | alpha-CP1; CBF; CCAAT-binding factor; CP1 |
| 5 | Sp1 | M00008, M00196, M00932, M00931, M00933 | Stimulating Protein 1; trans-acting transcription factor 1 |
| 6 | Hand1:E47 | M00222 | Hand1:E47 heterodimer. Hand1 is thought to bind to the left half (positions 1–8), E47 to the right half (position 9–16) |
| 7 | MEF-2 | M00405 M00006, M00232, M00406, M00941, M00233, M00231 | Myogenic enhancer factor 2 |
| 8 | USF | M00796, M00187, M00217, M00121, M00122 | Upstream stimulating factor |
| 9 | USF2 | M00726 | Upstream stimulatory factor 2; Fos-interacting protein |
| 10 | Tal-1beta:E47 | M00065 | Tal-1alpha:E47 heterodimer. Random 35-mers bound by in vitro co-translated Tal-1beta and E47 after 6 CASTing cycles |
| 11 | Ebox | M01034 | Ebox binding protein |
| 12 | Myogenin | M00712 | Myf-4 (human); MyoG; myogenin |
| 13 | E2A | M00804, M00973 | E2-alpha; immunoglobulin enhancer binding factors E12/E47 |
| 14 | NKX25 | M01043 | Csx; NK2 transcription factor related, locus 5 (Drosophila) |
| 15 | Nkx2-5 | M00240, M00241 | Homeo domain factor Nkx-2.5/Csx, tinman homolog |
| 16 | TATA | M00252, M00216 | TATA-binding protein; TATA-box-binding protein; TBP; TFIID; TFIIDtau |
| 17 | TBX5 | M01019, M01020, M01044 | T-box protein 5 |
| 18 | MyoD | M00001, M00184, M00929 | Myoblast determining factor |
| 19 | SRF | M00152, M00810, M01007, M00186, M00215, M00922 | Serum Responsive Factor |
| 20 | TBP | M00471, M00980 | TATA-binding protein |
| 21 | GATA-4 | M00632 | GATA-binding factor 4 |
| 22 | GATA | M00789 | GATA-binding factor |
| 23 | E47 | M00071, M00002 | E2A; immunoglobulin enhancer-binding factor E12/E47 |
| 24 | E12 | M00693 | E2A; immunoglobulin enhancer-binding factor E12/E47 |
Figure 2Stability measurements using the first perturbation procedure. The boxes with red, green purple colour are the stability measurements of YY1, myogenin and MyoD, respectively.
Figure 3Stability measurements using the second perturbation procedure. The boxes with red, green, purple colour are the stability measurements of YY1, myogenin and MyoD, respectively.
A summary of the stability analysis using mNCA with different number of perturbations for YY1, myogenin and MyoD.
| Stability Measurement of transcription factor's activity/No. of perturbations | 10 | 15 | 20 | 30 | 50 | |
| YY1 | 75% quantile | 0.9981 | 0.9978 | 0.9977 | 0.9979 | 0.9977 |
| 25% quantile | 0.9928 | 0.9913 | 0.9886 | 0.9905 | 0.9870 | |
| myogenin | 75% quantile | 0.9776 | 0.9623 | 0.9745 | 0.9633 | 0.9662 |
| 25% quantile | 0.8680 | 0.8110 | 0.8250 | 0.8078 | 0.7959 | |
| MyoD | 75% quantile | 0.9908 | 0.9898 | 0.9894 | 0.9904 | 0.9894 |
| 25% quantile | 0.9632 | 0.9634 | 0.9621 | 0.9620 | 0.9542 | |
Figure 4Gene expression patterns of (a) YY1, (c) myogenin, and (e) MyoD, respectively; estimated TFAs of (b) YY1, (d) myogenin, and (f) MyoD, respectively. Note: x-axis – time points; y-axis – log expression ratio (a, c and e) or log TFA ratio (b, d, e).
Figure 5Gene expression pattern of calpain II. Note: x-axis – time points; y-axis – log expression ratio.